Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 12/20 | 0.47 |
| ▸ | RAF1 | P04049 | 7/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | TAOK1 | Q7L7X3 | 3/20 | 0.45 |
| ▸ | TAOK3 | Q9H2K8 | 3/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL546548 | 0.89 | TAOK1 (0.57) | BRAFRAF1MAPK14TAOK1TAOK3 | |
| SCHEMBL5428112 | 0.89 | BRAF (0.50) | BRAFRAF1MAPK14TAOK1TAOK3 | |
| SCHEMBL545415 | 0.87 | BRAF (0.54) | BRAFRAF1MAPK14KDRHDAC8 | |
| SCHEMBL546140 | 0.86 | BRAF (0.50) | BRAFRAF1MAPK14TAOK1TAOK3 | |
| SCHEMBL546701 | 0.86 | BRAF (0.51) | BRAFRAF1MAPK14TAOK1TAOK3 | |
| SCHEMBL545700 | 0.85 | BRAF (0.50) | BRAFRAF1MAPK14TAOK1TAOK3 | |
| SCHEMBL546161 | 0.84 | BRAF (0.51) | BRAFRAF1MAPK14TAOK1KDR | |
| SCHEMBL546005 | 0.83 | BRAF (0.53) | BRAFRAF1MAPK14KDRKCNH2 | |
| SCHEMBL546007 | 0.83 | BRAF (0.51) | BRAFRAF1MAPK14KDRHDAC8 | |
| SCHEMBL545680 | 0.83 | BRAF (0.51) | BRAFRAF1MAPK14KDRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | BRAF 215/4885RAF1 198/4885MAPK14 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.